114 results on '"Scheen, A. J."'
Search Results
2. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in patients with ASCVD
3. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
4. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
5. Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes
6. Double et triple agonistes : rôle du glucagon
7. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
8. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
9. Use of SGLT2 inhibitors after bariatric/metabolic surgery: Risk/benefit balance
10. Metabolic disorders induced by psychotropic drugs
11. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes: SGLT2 inhibitors in elderly and real life
12. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
13. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
14. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
15. Glucagon, from past to present: a century of intensive research and controversies
16. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
17. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
18. Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death?
19. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
20. Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers
21. Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?
22. Médicaments anti-obésité : leçons des échecs pour l’avenir
23. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
24. Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
25. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies
26. Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
27. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
28. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
29. Sulphonylureas in the management of type 2 diabetes: To be or not to be?
30. Obésité et COVID-19 : le choc fatal entre deux pandémies
31. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view
32. Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective
33. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
34. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
35. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
36. L'épopée des insulines des années 1930 aux années 1980
37. Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2
38. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
39. Precision medicine: The future in diabetes care?
40. Instauration d’une insulinothérapie chez le patient diabétique de type 2 en médecine générale : Comparaison de l’étude belge InsuStar avec quelques études françaises et internationales
41. Insulinosensibilisateurs (metformine/glitazones) : niveau de preuve et controverse
42. Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique
43. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation
44. Traitement pharmacologique du diabète de type 2 après chirurgie bariatrique/métabolique
45. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
46. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
47. Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite
48. Diabètes pharmaco-induits : quatre classes médicamenteuses au cœur de notre pratique clinique
49. GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?
50. Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.